Skip to main content

Table 1 Used antiviral treatment

From: Therapy of chronic hepatitis C in people who inject drugs: focus on adherence

  PWID group (N = 101) Control group (N = 177) p
Previous IFN-α treatment 19 (18.8%) 69 (39%) 0.03
Direct-acting antivirals combination
 Paritaprevir/ritonavir + ombitasvir + dasabuvir 8 or 12 weeks (75/50/12.5/250 mg, three pills in the morning, one pill in the evening) 41 (40.6%) 83 (48.7%) < 0.01
 Sofosbuvir + ledipasvir 8 or 12 weeks (400/90 mg, one pill once daily) 18 (17.8%) 19 (10.7%)  
 Grazoprevir + elbasvir 12 weeks (100/50 mg, one pill once daily) 19 (18.8%) 57 (32.2%)  
 Sofosbuvir + velpatasvir 12 weeks (400/100 mg, one pill once daily) 18 (17.8%) 10 (5.6%)  
 Sofosbuvir + velpatasvir + voxilaprevir 8 or 12 weeks (400/100/100 mg, one pill once daily) 3 (3.0%) 4 (1.4%)  
 Other 2 (2.0%) 4 (1.4%)  
Treatment duration
 8 weeks 27 (26.7%) 36 (20.3%) N. S.
 12 weeks 74 (73.3%) 141 (79.7%)  
Use of ribavirin (twice daily according to body weight, 800–1200 mg) 19 (18.8%) 22 (12.4%) N. S.
  1. P value of < 0.05 was considered statistically significant and the results are displayed in bold
  2. PWID people who inject drugs group